Basilea Pharmaceutica AG (BSLN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Basilea Pharmaceutica AG

Siegfried Holding AG

Bachem Holding AG

Novartis AG

Newron Pharmaceuticals SpA

Lonza Group AG

Idorsia Ltd.

Santhera Pharmaceuticals Holding AG

Spexis Ltd.

Cosmo Pharmaceuticals NV

RELIEF THERAPEUTICS Holding SA

Why is Basilea Pharmaceutica AG ?

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.92

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.92
The company has been able to generate a Return on Equity (avg) of 31.93% signifying low profitability per unit of shareholders funds

Healthy long term growth as Net Sales has grown by an annual rate of 10.95% and Operating profit at 70.36%

Positive results in Dec 24

OPERATING CASH FLOW(Y) Highest at CHF 88.6 MM
ROCE(HY) Highest at 218.58%
INVENTORY TURNOVER RATIO(HY) Highest at 1.33%

With ROE of 70.44%, it has a Very Expensive valuation with a 6.27 Price to Book Value

Over the past year, while the stock has generated a return of 33.33%, its profits have risen by 7331%

Market Beating Performance

The stock has generated a return of 33.33% in the last 1 year, much higher than market (Switzerland SMI) returns of 10.00%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Basilea Pharmaceutica AG should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Basilea Pharmaceutica AG for you?

Medium Risk, High Return

Absolute

Risk Adjusted

Volatility

Basilea Pharmaceutica AG

-100.0%

1.18

29.48%

Switzerland SMI

11.48%

0.63

15.85%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

10.95%

EBIT Growth (5y)

70.36%

EBIT to Interest (avg)

1.92

Debt to EBITDA (avg)

10.62

Net Debt to Equity (avg)

-0.33

Sales to Capital Employed (avg)

1.09

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

40.20%

ROE (avg)

31.93%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

6.27

EV to EBIT

7.88

EV to EBITDA

7.52

EV to Capital Employed

10.99

EV to Sales

2.53

PEG Ratio

Dividend Yield

ROCE (Latest)

139.41%

ROE (Latest)

70.44%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for Basilea Pharmaceutica AG

Pre-Tax Profit

At CHF 52.94 MM has Grown at 347.29%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CHF MM)

Net Profit

At CHF 56.86 MM has Grown at 365.82%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CHF MM)

Operating Cash Flow

Highest at CHF 88.6 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CHF MM)

Net Sales

At CHF 132.25 MM has Grown at 81.84%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very positive

Net Sales (CHF MM)

Net Sales

Highest at CHF 132.25 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CHF MM)

Operating Profit

Highest at CHF 53.73 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (CHF MM)

Pre-Tax Profit

Highest at CHF 52.94 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CHF MM)

Net Profit

Highest at CHF 56.86 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CHF MM)

EPS

Highest at CHF 4.21

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CHF)

Inventory Turnover Ratio

Highest at 1.33%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 3.59%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Depreciation

Highest at CHF 1.8 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (CHF MM)

Here's what is not working for Basilea Pharmaceutica AG

Raw Material Cost

Grown by 5.31% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales